Details of the Drug Formulations

General Information of Drug (ID: DMLSUWZ)

Drug Name
PSI-7977 Drug Info
Synonyms
1190307-88-0; SOVALDI; PSI 7977; GS-7977; GS 7977; UNII-WJ6CA3ZU8B; WJ6CA3ZU8B; CHEBI:85083; Sofosbuvir (PSI-7977, GS-7977); Hepcvir; Hepcinat; HSDB 8226; 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; Sofosbuvir [USAN:INN]; Resof; SoviHep; Sovaldi (TN); Sofosbuvir (JAN/USAN); Sofosbuvir(PSI-7977); GTPL7368; SCHEMBL2010114; CHEMBL1259059; AMMD00019; EX-A389; MolPort-028-720-482; isopropyl (2S)-2-[[[(2R,
Indication
Disease Entry ICD 11 Status REF
HCV 1-6 infection 1E51 Approved [1]
Hepatitis C virus infection 1E51.1 Phase 2 [2]
Cross-matching ID
PubChem CID
45375808
ChEBI ID
CHEBI:85083
CAS Number
1190307-88-0
TTD ID
D0D4YZ
INTEDE ID
DR1495
ACDINA ID
D00634

Full List of Drug Formulations Containing This Drug

Sofosbuvir 400 mg tablet
Company Formulation ID FDA Description
Gilead Sciences F20314 Magnesium stearate; Mannitol; Ferric oxide yellow; Talc; Titanium dioxide; Water; Croscarmellose sodium; Silicon dioxide; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
------------------------------------------------------------------------------------

References

1 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2 2011 Pipeline of Pharmasset.